OneCell Diagnostics

About OneCell Diagnostics

OneCell Diagnostics, Inc. operates in the precision oncology sector, providing advanced liquid biopsy diagnostics. Founded in 2021 by Mohan Uttarwar, Aravindan Vasudevan, Dr. Jayant Khandare, and Dr. Gowhar Shafi, the company is a joint venture that combines the expertise of a Circulating Tumor Cell (CTC) test provider and a multi-omics data analytics software company. With dual operations in Silicon Valley, USA, and India, OneCell is positioned to leverage the strategic benefits of both regions.

The company's core business revolves around its proprietary platform that performs single-cell, multi-omics analysis on CTCs captured from a simple blood draw. This technology integrates CTC-DNA, CTC-RNA, and cell surface protein testing, offering a more comprehensive view than many existing liquid biopsy methods. Its primary product family, including tests like OncoIndx Alfa and OncoIndx Ikon, provides detailed biomarkers for cancer diagnosis and monitoring. These tests serve oncologists and hospitals by supporting treatment response evaluation, disease progression tracking, and recurrence detection. Additionally, OneCell caters to biotech and pharmaceutical companies by providing tools for early-stage clinical trials. Its business model is B2B2C, delivering tests through healthcare professionals.

The founding team's background is central to the company's capabilities. Mohan Uttarwar (CEO) is also the co-founder of iNDX.AI, bringing deep experience in healthcare informatics and AI/ML technologies. Aravindan Vasudevan (COO), with a background in chemistry and business, co-founded Actorius Innovations and Research, which developed India's first indigenous DCGI-approved CTC test. This foundation in both advanced diagnostics and data analytics underpins OneCell's approach. The company has already processed tests for nearly 10,000 patients in India, demonstrating the technology's real-world applicability and cost-effectiveness. A notable milestone was securing $16 million in a Series A funding round in late 2024, which is intended to finance expansion into the U.S. market.